• Member Login
• Sitemap
• Contact
• RSS feed

MDxHealth Confirms Progress on Companion Diagnostics Partnering

28/09/2011

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, confirmed today that it continues to make progress on partnering of its technology and companion diagnostics tests with pharmaceutical companies.

The company confirms that discussions are ongoing with several potential pharmaceutical partners that may or may not result in an agreement. An article in Reuters today stated that MDxHealth expects to “see a new pharma deal this year”, with CEO Jan Groen quoted as saying “multiple deals lined up, and one is close, … we’re reaching an agreement”. The Belgian FSMA requested MDxHealth to confirm that there is no privileged information at this stage. Since early 2011, MDxHealth has disclosed on its website that MDxHealth expected a new pharmaceutical deal in 2011. MDxHealth will immediately inform the market when any privileged information becomes available, such as the signing of a new agreement.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing and companion diagnostics for personalized medicine. The company’s numerous cancer tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck KGaA, Qiagen, Pfizer and other industry leaders.

Source: MDxHealth